The independent platform for news, articles and advice for professionals in laboratory medicine

Review of national cancer screening programmes in England welcomed

Oncimmune, a leading global immunodiagnostics group, has welcomed the publication of the Independent Review of Adult Screening Programmes in England, which makes recommendations on overhauling national cancer screening programmes to aid earlier diagnosis and treatment. Oncimmune's EarlyCDT Lung test, which uses a simple blood sample, can detect lung cancer on average four years or more before standard clinical diagnosis.

More than 12,000 people in Scotland at high risk of developing lung cancer were tested with EarlyCDT Lung in the recently announced Early Detection of Cancer of the Lung Scotland (ECLS) trial. The study showed that more people were diagnosed at an early stage of the disease in the two years after taking the test than those in the control arm who received standard clinical care. The findings were presented last month at the World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, and have now been submitted for publication in a leading medical journal.

Oncimmune is also working to make EarlyCDT Lung available to help diagnose lung cancer earlier in a range of other countries, including the United States, Spain, Russia and China. Oncimmune's patented technology harnesses the power of the immune system to detect evidence of the body's natural response to cancer. Tests to diagnose other forms of cancer, including ovarian, breast and prostate using a simple blood test are in development.

A link to the Report of The Independent Review of Adult Screening Programmes in England can be found online.

www.england.nhs.uk/wp-content/uploads/2019/02/report-of-the-independent-review-of-adult-screening-programme-in-england.pdf

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025